|
|
|
|
|||||
|
|
|
Revvity, Inc. RVTY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.01, which beat the Zacks Consensus Estimate of 96 cents by 5.2%. The bottom line improved 3.1% from the year-ago quarter’s level. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
GAAP EPS from continuing operations was 35 cents compared with 21 cents in the prior-year period.
Based in Waltham, MA, this leading MedTech company reported revenues of $664.7 million, up 2.3% year over year and 4% organically. The top line beat the Zacks Consensus Estimate by 0.4%.
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $340 million, up 2% organically from the year-ago quarter’s level.
Adjusted operating income amounted to $106 million, up 5% from the prior-year quarter’s figure.
Revvity Inc. price-consensus-eps-surprise-chart | Revvity Inc. Quote
Diagnostics
This segment’s revenues totaled $324 million, up 3% on a year-over-year basis. Organically, the top line increased 5% year over year.
Adjusted operating income amounted to $74 million, down 2.6% from the year-ago quarter’s figure.
Selling, general and administrative expenses totaled $249.7 million, down 4.2% year over year. Research and development expenses amounted to $53.6 million, down 6.4% from the year-ago quarter’s reported number.
Adjusted operating income improved 2.5% to $169.9 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 25.6%, expanding 10 basis points.
The company exited the first quarter of 2025 with cash and cash equivalents of $1.14 billion compared with $1.16 billion at the end of the prior quarter.
Net cash used in operating activities totaled $134.1 million compared with $150.1 million in the year-ago quarter.
Revvity reiterated its earnings outlook but updated its revenue guidance for 2025.
The company expects adjusted EPS to be in the range of $4.90-$5.00. Revenues are now anticipated to be in the band of $2.83-$2.87 billion (previously $2.80-$2.85 billion). The Zacks Consensus Estimate for EPS and revenues is pegged at $4.93 and $2.82 billion, respectively.
Revvity exited the first quarter of 2025 on a strong note, with both earnings and sales beating estimates and improving year over year. The company raised its revenue outlook due to a favorable currency movement. The projection is now expected to grow 3-5% organically.
Share of RVTY were up 5.9% during pre-market trading. The company’s shares have lost 14.6% so far this year compared with the industry’s decline of 1.6%.
Solid execution across both Life Sciences and Diagnostics segments underscores the strength of its diversified portfolio. With momentum clearly building and management reaffirming full-year targets, Revvity is well-positioned to navigate ongoing challenges and capitalize on emerging opportunities, setting a confident tone for the remainder of 2025.
Last month, RVTY announced the launch of its EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) in Europe to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. This should bring additional sales in the upcoming quarter, driving top-line growth further. Moreover, the favorable ruling for RVTY in February in a litigation with its partner, Cloud Software Group, ensured uninterrupted access to the latter’s Spotfire software. This will support Revvity and its customers’ operational continuity and service quality.
Earlier this month, RVTY announced the FDA approval for its Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test. The test is already available in certain international markets, and with this approval, it will start commercializing in the U.S. market.
RVTY carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the same medical industry are Fresenius Medical Care FMS, Masimo MASI and Glaukos GKOS.
Fresenius Medical, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 28.9% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
FMS’ earnings beat estimates in three of the trailing four quarters and met in one, delivering an average surprise of 15.67%. The company is expected to release first-quarter results next month.
FMS’ shares have gained 6% so far this year.
Masimo, sporting a Zacks Rank of 1 at present, has an estimated growth rate of 20% for 2025.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 14.41%. Its shares have risen 58.5% compared with the industry’s 3.9% growth year to date. The company is expected to release first-quarter results in May.
MASI’s shares have lost 8% so far this year.
Glaukos, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 48.9% for 2025. It delivered a trailing four-quarter average earnings surprise of 8.11%. The company’s earnings beat estimates in two of the trailing four quarters, met in one and missed in the other, delivering an average surprise of 8.11%. The company is expected to release first-quarter results on April 30.
GKOS’ shares have lost 40.1% so far this year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 9 hours | |
| 9 hours | |
| 11 hours | |
| 11 hours | |
| 11 hours | |
| 12 hours | |
| 13 hours | |
| 13 hours | |
| 15 hours | |
| 15 hours | |
| 16 hours | |
| 16 hours | |
| 17 hours | |
| Apr-27 | |
| Apr-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite